New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments
Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.
Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial
With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.
MindMed Initiates Second Phase 3 Trial of Psychedelic MM120 for Generalized Anxiety Disorder
The first patient was dosed in the Panorama study assessing MM120 ODT, a form of LSD, for the treatment of GAD.
AI-Assisted Mammography Boosts Breast Cancer Detection by 29% in Large Study
Results from the MASAI clinical trial also showed that AI-assisted screening reduced screen-reading workload without increasing the rate of false-positives.
World Cancer Day 2025: 7 Screening Recommendations from the USPSTF
World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.
Inhaled Psychedelic GH001 Significantly and Rapidly Reduces Symptoms in Treatment Resistant Depression in Phase 2b Clinical Trial
GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.
FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose
Your daily dose of the clinical news you may have missed.
Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD
Tepper, principal investigator for phase 3 trials of Symbravo as acute treatment for migraine in adults, reviews the new drug's dual MOA and target patient populations.
Optimizing PTSD Treatment: The Role of Brexpiprazole and Sertraline in Future Guidelines
Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.
COVID-19 Associated with Higher Long-Term Mortality Than Flu or RSV: New Data
Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.
Where Will the New Nonopioiod Suzetrigine (Journavx) Fit Best Along the Acute Pain Management Continuum? Phase 3 Investigator Shares Thoughts
Suzetrigine (Journavx) PI Todd Bertoch, MD, identifies the sweet spot where he thinks the new NaV1.8 inhibitor will be most effective in post-surgical and other moderate-to-severe acute pain.
Global Migraine Burden Rising Fastest Among Men and Adolescents, New Research Finds
The global burden of migraine rose by 58% between 1990 and 2021 to more than 1 billion, a pace projected to continue and most rapidly among men and young people.
Stool Tests Still Top Choice for CRC Screening: Daily Dose
7 Drugs Approved for Primary Care: Q4 2024
An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.
Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds
Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.
Symbravo (AXS-07) for Treatment of Acute Migraine in Adults: Phase 3 Trial Primer
The pivotal INTERCEPT and MOMENTUM phase 3 clinical trials served as foundational evidence for the efficacy of the combination therapy across migraine presentations.
Pain Expert Edward Mariano, MD, MAS, Highlights Journavx and the Newly-Approved Nonopioid's Mechanism of Action
Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.
FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose
Journavx Approval: Lead Investigator Highlights Pivotal Phase 3 Clinical Trials
Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.
FDA Approves Journavx, First-in-Class Nonopioid Analgesic for Moderate-to-Severe Acute Pain
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
